Orchid Chemicals & Pharmaceuticals is currently trading at its upper circuit limit of Rs. 53.60, up by 4.85 points or 9.95% from its previous closing of Rs. 48.75 on the BSE.
The scrip opened at Rs. 53.00 and has touched a high and low of Rs. 53.60 and Rs. 51.55 respectively. So far 98709 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 85.80 on 15-Mar-2013 and a 52 week low of Rs. 35.00 on 06-Aug-2013.
Last one week high and low of the scrip stood at Rs. 53.60 and Rs. 47.40 respectively. The current market cap of the company is Rs. 377.62 crore.
The promoters holding in the company stood at 32.28% while Institutions and Non-Institutions held 7.83% and 55.31% respectively.
Orchid Chemicals and Pharmaceuticals has received Corporate Debt Restructuring (CDR) approval, paving the way for the sale of a portion of its businesses to Hospira Healthcare India, and cut debt.
The company will be repaying a portion of the debt (i.e Rs 681 crore) to the lenders with proceeds from the sale, while the remaining Rs 2,866 crore will be restructured.
The CDR scheme also includes funding to meet working capital borrowings. The restructured debt, along with funded loans, will have to be repaid in eight years.
Orchid Chemicals & Pharmaceuticals is a pharmaceutical company engaged in development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs. The company was incorporated in the year 1992 as a 100% export-oriented unit (EOU).
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: